STAT+: Pharmalittle: We’re reading about an FDA plan for ultra-rare drugs, Novo cutting GLP-1 drug prices, and more

The Trump administration has released detailed guidance aimed at facilitating the approval of bespoke medicines designed to treat individual patient mutations. This initiative is part of a broader effort to address the needs of patients with ultra-rare diseases, potentially expanding the market for pharmaceutical companies involved in developing personalized medicine. The focus on ultra-rare drugs reflects ongoing discussions about healthcare reform and the evolving landscape of drug pricing in the United States. In his State of the Union address, President Trump claimed that his administration had successfully reduced U.S. prescription drug costs from the highest in the world to the lowest. This assertion has sparked debate among experts and analysts regarding its accuracy, highlighting the administration's emphasis on drug pricing as a significant concern. The claim has become a focal point in discussions about healthcare policies and the impact of the administration's initiatives on drug costs. Pharmaceutical companies are responding to the changing dynamics of drug pricing and healthcare policies by increasing their expenditures on lobbying firms with connections to the White House. This trend indicates a broader strategy within the industry to influence policy and regulatory decisions that may affect their operations and profitability. The heightened spending on lobbying coincides with the administration's focus on drug pricing as a key issue. Additionally, Novo Nordisk has been noted for cutting prices on its GLP-1 drugs, which are used for obesity treatment. This price reduction may be part of a competitive strategy in response to the current administration's policies and the overall changes in the healthcare market. The actions taken by both the administration and pharmaceutical companies reflect the ongoing complexities of drug pricing and healthcare reform in the United States.